About Us
Science & Technology
Approach
Publications
Investors & Media
Careers
Program Manager
Contact Us
Investors & Media
News Releases
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-
December 3, 2024
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 11, 2024
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 7, 2024
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
June 3, 2024
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
May 1, 2024
View all News
Corporate Presentations
Beyond Cancer Corporate Presentation
February 2025
View
Beyond Cancer Corporate Event
ASCO 2024 – Chicago, IL
May 31, 2024
View
A Cancer Treatment with a Powerful Systemic Response
Our Approach
